Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2371 to 2385 of 8236 results

  1. Orforglipron for treating type 2 diabetes [TSID12130]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Mosunetuzumab for treating relapsed or refractory follicular lymphoma [TSID 12081]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Nifedipine - Lidocaine for Chronic Anal Fissure [TSID 12093]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]

    In development Reference number: GID-TA11497 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. PillCam COLON 2 for investigation of the colon through direct visualisation

    In development Reference number: GID-DG10083 Expected publication date: TBC

    Diagnostics guidance
    In development

  6. Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]

    In development Reference number: GID-TA11583 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [TSID12157]

    Awaiting development Reference number: GID-TA11717 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]

    Awaiting development Reference number: GID-TA11490 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Subcutaneous nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID 12178]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]

    Awaiting development Reference number: GID-TA10961 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]

    Awaiting development Reference number: GID-TA11558 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Alcohol Use Disorders (update)

    In development Reference number: GID-NG10445 Expected publication date: TBC

    NICE guideline
    In development

  13. Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]

    Awaiting development Reference number: GID-TA11623 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Cyanoacrylate glue for hernia mesh fixation (MT707)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  15. O2Matic pro 100 (MT746)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation